225 related articles for article (PubMed ID: 31607527)
1. Associations between absolute neutrophil count and lymphocyte-predominant breast cancer.
Yoon CI; Park S; Cha YJ; Lee HS; Bae SJ; Cha C; Lee DY; Ahn SG; Jeong J
Breast; 2020 Apr; 50():141-148. PubMed ID: 31607527
[TBL] [Abstract][Full Text] [Related]
2. Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer.
Fukui K; Masumoto N; Shiroma N; Kanou A; Sasada S; Emi A; Kadoya T; Yokozaki M; Arihiro K; Okada M
Breast Cancer; 2019 Sep; 26(5):573-580. PubMed ID: 30868399
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
Ingold Heppner B; Untch M; Denkert C; Pfitzner BM; Lederer B; Schmitt W; Eidtmann H; Fasching PA; Tesch H; Solbach C; Rezai M; Zahm DM; Holms F; Glados M; Krabisch P; Heck E; Ober A; Lorenz P; Diebold K; Habeck JO; Loibl S
Clin Cancer Res; 2016 Dec; 22(23):5747-5754. PubMed ID: 27189162
[TBL] [Abstract][Full Text] [Related]
4. Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis.
Ohtani H; Mori-Shiraishi K; Nakajima M; Ueki H
Pathol Int; 2015 Dec; 65(12):644-51. PubMed ID: 26530981
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.
Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M
Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657
[TBL] [Abstract][Full Text] [Related]
6. The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively.
Kanou A; Masumoto N; Fukui K; Yokozaki M; Sasada S; Emi A; Kadoya T; Arihiro K; Okada M
J Med Ultrason (2001); 2022 Oct; 49(4):709-717. PubMed ID: 36002708
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
Ahn SG; Cha YJ; Bae SJ; Yoon C; Lee HW; Jeong J
BMC Cancer; 2018 Mar; 18(1):320. PubMed ID: 29573739
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
De Angelis C; Nagi C; Hoyt CC; Liu L; Roman K; Wang C; Zheng Y; Veeraraghavan J; Sethunath V; Nuciforo P; Wang T; Tsimelzon A; Mao S; Hilsenbeck SG; Trivedi MV; Cataldo ML; Pavlick A; Wolff AC; Weigelt B; Reis-Filho JS; Prat A; Gutierrez C; Osborne CK; Rimawi MF; Schiff R
Clin Cancer Res; 2020 Feb; 26(3):738-745. PubMed ID: 31653641
[TBL] [Abstract][Full Text] [Related]
9. Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study.
Huang J; Chen X; Fei X; Huang O; Wu J; Zhu L; He J; Chen W; Li Y; Shen K
Cancer Res Treat; 2019 Oct; 51(4):1336-1346. PubMed ID: 30744321
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
[TBL] [Abstract][Full Text] [Related]
11. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.
Pruneri G; Vingiani A; Bagnardi V; Rotmensz N; De Rose A; Palazzo A; Colleoni AM; Goldhirsch A; Viale G
Ann Oncol; 2016 Feb; 27(2):249-56. PubMed ID: 26598540
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer.
Chen Y; Klingen TA; Aas H; Wik E; Akslen LA
J Pathol Clin Res; 2021 Sep; 7(5):517-527. PubMed ID: 34076969
[TBL] [Abstract][Full Text] [Related]
13. The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer.
Lee KH; Kim EY; Yun JS; Park YL; Do SI; Chae SW; Park CH
BMC Cancer; 2018 Oct; 18(1):938. PubMed ID: 30285668
[TBL] [Abstract][Full Text] [Related]
14. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
15. Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Herrero-Vicent C; Guerrero A; Gavilá J; Gozalbo F; Hernández A; Sandiego S; Algarra MA; Calatrava A; Guillem-Porta V; Ruiz-Simón A
Ecancermedicalscience; 2017; 11():759. PubMed ID: 28900472
[TBL] [Abstract][Full Text] [Related]
16. PERCEPTION Trial protocol: Comparison of predictive and prognostic capacities of neutrophil, lymphocyte, and platelet counts and tumor-infiltrating lymphocytes in triple negative breast cancer.
Lusho S; Durando X; Bidet Y; Molnar I; Kossai M; Bernadach M; Lacrampe N; Veyssiere H; Cavaille M; Gay-Bellile M; Radosevic-Robin N; Abrial C
Medicine (Baltimore); 2020 Dec; 99(50):e23418. PubMed ID: 33327268
[TBL] [Abstract][Full Text] [Related]
17. An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
Fukui R; Watanabe T; Morimoto K; Fujimoto Y; Nagahashi M; Ishikawa E; Hirota S; Miyoshi Y
Breast Cancer; 2023 Sep; 30(5):703-713. PubMed ID: 37115435
[TBL] [Abstract][Full Text] [Related]
18. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
[TBL] [Abstract][Full Text] [Related]
19. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
[TBL] [Abstract][Full Text] [Related]
20. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
